Cargando…

Associations of Warfarin Use with Risks of Ischemic Cerebrovascular Events and Major Bleeding in Patients with Hyperthyroidism-Related Atrial Fibrillation

The use of oral anticoagulants for patients with new-onset hyperthyroidism-related atrial fibrillation (AF) is controversial. We aimed to evaluate the clinical benefits of warfarin therapy in this population. This retrospective cohort study used a data-cut of Taiwan Health and Welfare Database betwe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Sian-De, Lin, Shwu-Jiuan, Ray, Chin-Ying, Lin, Fang-Tsyr, Lin, Weei-Chin, Wang, Li-Hsuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687236/ https://www.ncbi.nlm.nih.gov/pubmed/36359190 http://dx.doi.org/10.3390/biomedicines10112670

Ejemplares similares

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Super-enhanced MARCO variant drives triple-negative breast cancer progression
por: Lin, Weei-Chin, et al.
Publicado: (2022)

A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants
por: Claxton, J’Neka S., et al.
Publicado: (2018)

Atrial Fibrillation and Hyperthyroidism
por: N, Jayaprasad, et al.
Publicado: (2005)

The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation
por: Simon, Teresa A., et al.
Publicado: (2016)

The mechanisms of atrial fibrillation in hyperthyroidism
por: Bielecka-Dabrowa, Agata, et al.
Publicado: (2009)

Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin
por: Lai, Hoang M, et al.
Publicado: (2009)

TRIP6 antagonizes the recruitment of A20 and CYLD to TRAF6 to promote the LPA2 receptor-mediated TRAF6 activation
por: Lin, Fang-Tsyr, et al.
Publicado: (2016)

Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer
por: Liu, Kang, et al.
Publicado: (2021)

Association of inflammation with atrial fibrillation in hyperthyroidism
por: Ozaydin, Mehmet, et al.
Publicado: (2012)

Clinical outcomes of atrial fibrillation with hyperthyroidism
por: Zubair Khan, Muhammad, et al.
Publicado: (2021)

Inadequate oral anticoagulation with warfarin in women with cerebrovascular event and history of atrial fibrillation: the FibStroke study
por: Bah, Aissa, et al.
Publicado: (2021)

Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin‐naïve or warfarin‐experienced patients
por: Perino, Alexander C., et al.
Publicado: (2022)

Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non–vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage
por: Tsai, Chuan-Tsai, et al.
Publicado: (2020)

Warfarin and the Risk of Death, Stroke, and Major Bleeding in Patients With Atrial Fibrillation Receiving Hemodialysis: A Systematic Review and Meta-Analysis
por: Lei, Hong, et al.
Publicado: (2018)

Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study
por: Wang, Shirley V, et al.
Publicado: (2016)

Acute ischemic stroke in young adult: Atrial fibrillation, hyperthyroidism, and COVID-19 collaboration
por: Betül Gunduz, Zahide, et al.
Publicado: (2021)

Warfarin and atrial fibrillation: from ideal to real the warfarin affaire
por: Molteni, Mauro, et al.
Publicado: (2014)

Risk of Thromboembolism in Non-Valvular Atrial Fibrillation With or Without Clinical Hyperthyroidism
por: Lin, Yu-Sheng, et al.
Publicado: (2021)

The use of warfarin in veterans with atrial fibrillation
por: Bravata, Dawn M, et al.
Publicado: (2004)

Atrial fibrillation and hyperthyroidism: A literature review
por: Reddy, Vivek, et al.
Publicado: (2017)

The Atrial Fibrillation Risk Score for Hyperthyroidism Patients
por: Derevitskii, Ilya V., et al.
Publicado: (2020)

Challenges in the Management of Atrial Fibrillation With Subclinical Hyperthyroidism
por: Gencer, Baris, et al.
Publicado: (2022)

Cerebrovascular Dysfunction in Atrial Fibrillation
por: Junejo, Rehan T., et al.
Publicado: (2020)

Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding
por: Kang, Hye-Rim, et al.
Publicado: (2023)

Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy
por: Chowdhury, Pinki, et al.
Publicado: (2014)

Warfarin Use in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review of Stroke and Bleeding Outcomes
por: Tsai, Chieh, et al.
Publicado: (2017)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

All-Cause and Bleeding-Related Health Care Costs in Warfarin-Treated Patients with Atrial Fibrillation
por: Ghate, Sameer R., et al.
Publicado: (2011)

Yearly Incidence of Stroke and Bleeding in Atrial Fibrillation with Concomitant Hyperthyroidism: A National Discharge Database Study
por: Zhang, Juqian, et al.
Publicado: (2022)

Assessment of one-year risk of ischemic stroke versus major bleeding in patients with atrial fibrillation
por: Sargsyan, Davit, et al.
Publicado: (2022)

The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study
por: Jun, Min, et al.
Publicado: (2015)

Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study
por: Lai, Kuan-Cheng, et al.
Publicado: (2018)

Effectiveness and Safety of Immunosuppressants and Biological Therapy for Chronic Spontaneous Urticaria: A Network Meta-Analysis
por: Lin, Wen-Kuang, et al.
Publicado: (2022)

Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes
por: Gallagher, Arlene M, et al.
Publicado: (2014)

Predictors of Atrial Fibrillation Recurrence in Hyperthyroid and Euthyroid Patients
por: Gürdoğan, Muhammet, et al.
Publicado: (2016)

Predictors of Atrial Fibrillation Recurrence in Hyperthyroid and Euthyroid Patients
por: Cerit, Levent
Publicado: (2016)

The Outcome of Electrical Cardioversion in Hyperthyroid Induced Atrial Fibrillation
por: Shah, Hriday, et al.
Publicado: (2023)

Warfarin: Major bleeding complication manifesting as retroperitoneal bleed: case report
Publicado: (2020)

Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
por: Alberts, Mark, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nr8cdfe7f3ep9b8da6kre941kd